BNTX - BioNTech SE ADR Stock Price Quote - NASDAQ | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Investor

Is it the right time to buy or sell?

Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

BioNTech's mRNA Technology Supports a Broad Pipeline Beyond Coronavirus

Sector Strategist Karen Andersen

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Karen Andersen, CFA | Apr 1, 2022

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for COVID-19, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships.

Unlock Our Full Analysis With Morningstar Investor

BioNTech SE ADR's Company Profile

Business Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact

An der Goldgrube 12
Mainz, RP, D-55131, Germany

T +49 613190840

Investors@biontech.de

www.biontech.de

Sector Healthcare

Industry Biotechnology

Most Recent Earnings Mar 31, 2022

Fiscal Year End Dec 31, 2022

Stock Type —

Employees 3,082

BioNTech SE ADR's Related News

Markets Brief: Dodging the Bear, for Now at Least

Stocks stage a comeback to avoid falling into bear territory as TreeHouse Foods, BioNTech rally.

Markets Brief: Will the Volatility Continue?

Latest CPI report is on deck. Devon Energy and Occidental rally. Lyft shares plunge.

Markets Review/Preview: All Eyes on the Jobs Report

More strong readings on the labor market are expected as the Fed is seen moving higher, faster on rates.

Markets Review/Preview: Yields March Higher, Oil Slides

Chinese ADRs bounce back, Nvidia and Moderna rise, and energy stocks slump.

Stock Strategist Industry Reports

Will Vaccine Manufacturers' Windfalls Continue Beyond 2022?

We think the COVID-19 treatment market will have more longevity.

Investing Specialists

Weekly Wrap: Undervalued Stocks for 2022, Outlook for the Market and Economy, and Your 2022 Financial Calendars

And also Tesla.

Morningstar.com

Stock Analyst Update

Fair Value Increases for Pfizer, BioNTech, and Moderna

Increased contracts for COVID-related products are just part of the reason for the upgrades.

The Year in U.S. Stock Funds

The Best Stocks of 2021 in Morningstar’s Coverage List

Moderna and BioNTech were among a top performers list dominated by tech, energy, and consumer names.

Stock Analyst Update

Encouraging Lab Data From Pfizer/BioNTech on Omicron

We're maintaining our fair value estimates for mRNA vaccine firms.

Stock Analyst Update

Omicron Variant Could Require Its Own Vaccine

What does this mean for leading vaccine makers Pfizer, BioNTech, and Moderna?

Manager Question of the Month: How Do Managers Approach Boom-or-Bust Biotech Stocks?

Benchmark rebuild in June put pressure on some small-cap managers.

Big Biotech Shares Take a Wild Ride

As the post-pandemic pharma landscape takes shape, Moderna and BioNTech slide, Pfizer rallies.

Stock Analyst Update

Maintaining Our Vaccine Forecast

We're not making any changes to our fair value estimates for Moderna, BioNTech, or Pfizer, and we continue to see no-moat Moderna and BioNTech as significantly overvalued at recent prices.

Stock Strategist Industry Reports

COVID-19 Vaccine Efficacy Solid Even as Delta Extends Pandemic

Hopes for eradication fade, further highlighting the benefits of vaccination and boosters.

Investing Specialists

Weekly Wrap: Buffett Buys, Falling Fund Fees, and Retirement Tips

We recap the week on Morningstar.com and note the most popular stocks, funds, and exchange-traded funds.

Morningstar.com

Stock Analyst Update

FDA Gives Full Approval to Pfizer COVID-19 Vaccine

The mRNA technology that formed the basis of the vaccine provides support to Pfizer's established wide moat and also contributes to BioNTech's positive moat trend.

Stock Analyst Update

COVID-19 Vaccine Booster Plans Match Our Expectations

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

Q2 Top Stock Performers on Morningstar's Coverage List

Energy and tech stocks lead as the U.S. market rally continued

Are Vaccinemakers Attractive Today?

Here are a few drugmakers we like that are undervalued.

Sachin Nagarajan

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.